MedTrace Logo

PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC

NCT07645222 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 396

Last updated 2026-07-06

No results posted yet for this study

Summary

This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20122 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Conditions

Interventions

DRUG

HS-20122+Aumolertinib

EGFR mut NSCLC, receive HS-20122+Aumolertinib

DRUG

HS-20122+Adbrelimab

EGFRwt NSCLC,receive HS-20122+Adbrelimab

DRUG

HS-20122+Adbrelimab+Platinum-based Chemo

EGFR wt NSCLC,receive HS-20122+Adbrelimab+ Platinum-based Chemo

Sponsors & Collaborators

  • Hansoh BioMedical R&D Company

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-15
Primary Completion
2028-10-31
Completion
2029-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07645222 on ClinicalTrials.gov